NCT00813098

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 155 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.

Conditions

• Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	LX1031 High Dose	A high dose of LX1031; daily oral intake for 28 days
DRUG	LX1031 Low Dose	A low dose of LX1031; daily oral intake for 28 days.
DRUG	Placebo	Matching placebo dosing with daily oral intake

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-07-01
• Completion: 2010-08-01
• First posted: 2008-12-22
• Last updated: 2010-12-02
• Results posted: 2010-12-02

Locations

36 sites across 1 country: United States